金河生物科技股份有限公司关于股票交易异常波动的公告

Group 1 - The company's stock (stock code: 002688) experienced an abnormal trading fluctuation, with a cumulative price increase of 26.48% over three consecutive trading days from April 1 to April 3, 2025 [2] - The company conducted a self-examination and confirmed that there were no corrections or supplements needed for previously disclosed information [3] - The company did not find any recent media reports that could have significantly impacted the stock price [4] Group 2 - The company's operational situation and external business environment have not undergone any significant changes recently [5] - The company and its major shareholders have not engaged in any undisclosed significant matters related to the company during the abnormal trading period [5] - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange regulations [6] Group 3 - The company is in the process of preparing its 2024 annual report and 2025 Q1 report, which will be disclosed on April 26, 2025 [7] - The company has not provided any undisclosed performance information to third parties outside of its auditing firm [7] - The designated information disclosure media for the company includes several financial newspapers and websites [7]